Share This Article:

Deep Venous Thrombosis in Breast Cancer Patients Using Tamoxifen, a Hypothesis

Full-Text HTML XML Download Download as PDF (Size:144KB) PP. 607-609
DOI: 10.4236/jct.2011.25081    4,457 Downloads   7,802 Views   Citations

ABSTRACT

Breast cancer is the most frequently diagnosed cancer in women and systematic therapy is an essential component of disease. Hormonal therapy, cytotoxic chemotherapy and the more recently introduced biological therapies are routinely employed in the vast majority of patients. Several pharmaceuticals that affect the estrogenic pathways have been studied as chemopreventive agents. Tamoxifen is an anti-estrogenic drug used in the treatment of estrogen receptor positive breast cancer patients. One of the important side-effects of tamoxifen is thromboembolic events like deep venous thrombosis. Tamoxifen also causes an increase in mean platelet volume. We hypothesize that thromboembolic effect of tamoxifen is via increase of mean platelet volume.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Sayin and B. Bakkal, "Deep Venous Thrombosis in Breast Cancer Patients Using Tamoxifen, a Hypothesis," Journal of Cancer Therapy, Vol. 2 No. 5, 2011, pp. 607-609. doi: 10.4236/jct.2011.25081.

References

[1] E. Chu and V. T. De Vita, “Physicians’ Cancer Chemotherapy Drug Manual,” Jones and Barlett Publishers, Sudbury, 2009.
[2] P. D. Stein, H. Huang, A. Afzal and H. A. Noor, “Incidence of Acute Pulmonary Embolism in a General Hospital: Relation to Age, Sex, and Race,” Chest, Vol. 116, No. 4, 1999, pp. 909-913. doi:10.1378/chest.116.4.909
[3] P. J. Powers, M. Gent, R. M. Jay, et al., ”A Randomized Trial of Less Intense Postoperative Warfarin or Aspirin Therapy in the Prevention of Venous Thromboembolism after Surgery for Fructured Hip,” Archives of internal Medicine, Vol. 149, No. 4, 1989, pp. 771-774. doi:10.1001/archinte.149.4.771
[4] W. H. Geerts, R. M. Jay, K. I. Code, et al., “A Comparison of Low-Dose Heparine With-Low-Molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Travma,” New England Journal of Medicine, Vol. 535, No. 10, 1996, pp. 701-707. doi:10.1056/NEJM199609053351003
[5] “Guidelines on Diagnosis and Management of Acute Pulmonary Embolism. Task Force on Pulmonary Embolism, European Society of Cardiology,” European Heart Journal, Vol. 21, No. 16, 2000, pp. 1301-1336. doi:10.1053/euhj.2000.2250
[6] B. A. Hutten, M. H. Prins, M. Gent, J. Ginsberg, J. G. Tijssen and H. R. Buller, “Incidence of Recurrent Thromboembolic and Bleeding Complications among Patients with Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis,” Journal of Clinical Oncology, Vol. 18, No. 17, 2000, pp. 3078-3083.
[7] C. Warlow, D. Ogston and A. S. Douglas, “Venous Thrombosis Following Strokes,” Lancet, Vol. 1, No. 7764, 1972, pp. 1305-1306. doi:10.1016/S0140-6736(72)91034-3
[8] M. R. Toglia and J. G. Weg, “Venous Thromboembolism during Pregnancy,” New England Journal of Medicine, Vol. 335, No. 2, 1996, pp. 108-114. doi:10.1056/NEJM199607113350207
[9] C. Demers, J. S. Ginsberg, J. Hirsh, P. Henderson and M. A. Blajchman, “Thrombosis in Antithrombin-III-Deficient Persons. Report of o Large Kindred and Literature Review,” Annals of Internal Medicine, Vol. 116, No. 9, 1992, pp. 754-761.
[10] M. den Heijer and M. B. Keijzer, “Hyperhomocysteinemia as a Risk Factor for Venous Thrombosis,” Clinical Chemistry and Laboratory Medicine, Vol. 39, No. 8, 2001, pp. 710-713. doi:10.1515/CCLM.2001.117
[11] J. S. Levine, D. W. Branch and J. Rauch, “The Anti-phospholipid Syndrome,” New England Journal of Medicine, Vol. 346, No. 10, 2002, pp. 752-763. doi:10.1056/NEJMra002974
[12] G. Endler, A. Klimesch, H. Sunder-Plassmann, et al., “Mean Platelet Volume Is an Independent Risk Factor for Myocardial Infarction but Not for Coronary Artery Disease,” British Journal of Haematology, Vol. 117, No. 2, 2002, pp. 399-404. doi:10.1046/j.1365-2141.2002.03441.x
[13] G. Cihan, M. B. Yilmaz, Y. Guray, et al., “Ortalama Trombosit Hacmi Akut Koroner Sendromlu Hastalarda Stabil Angina Pektorisli Hastalardan Daha Yuksektir,” Turk Kardiyoloji Dernegi Arsivi, Vol. 10, No. 1, 2003, p. 529.
[14] S. Keskin, M. Gurler, E. Temeloglu, A. Celebi, R. Alicanoglu and I. Ekizoglu, “Ortalama Trombosit Hacminin Koroner Arter Hastahigi Risk Faktorleriyle Iliskisi,” Tip Bilimleri Dergisi, Vol. 26, No. 4, 2006, pp. 380-384.
[15] S. K. Braekkan, E. B. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer and J. B. Hansen, “Mean Platelet Volume Is a Risk Factor for Venous Thromboembolism—The Tromso Study,” Journal of Thrombosis and Haemostasis, Vol. 8, No. 1, 2009, pp. 157-162.
[16] A. Uludag, M. B. Canoz, F. Erdenen, C. Muderrisoglu and B. Canoz, “Ortalama Trombosit Hacmi (MPV) Myokard Infarktusu Icin Bir Risk Faktoru Mu?” Nobel Medicus, Vol. 1, No. 3, 2005, pp. 20-23.
[17] B. Yavuz, D. T. Ertugrul, A. A. Yalcin, M. Kucukazman, N. Ata and K. Dal, “Increased Mean Platelet Volume in Rheumatic Mitral Stenosis: A Possible Factor for Thromboembolic Events,” Journal of Cardiology, Vol. 53, No. 2, 2009, pp. 204-207. doi:10.1016/j.jjcc.2008.10.012
[18] C. E. Holmes, J. C. Huang, T. R. Pace, A. B. Howard and H. B. Muss, “Tamoxifen and Aromatase Inhibitors Differentially Affect Vascular Endothelial Growth Factor and Endostatin Levels in Women with Breast Cancer,” Clinical Cancer Research, Vol. 14, No. 10, 2008, 3070-3076. doi:10.1158/1078-0432.CCR-07-4640
[19] B. Karagoz, O. Bilgi, A. Alacacioglu, et al., ”Mean Platelet Volume Increase after Tamoxifen, but Not after Anastrazole in Adjuvant Therapy of Breast Cancer,” Medical Oncology, Vol. 27, No. 2, 2010, pp. 199-202. doi:10.1007/s12032-009-9191-2
[20] A. Robinson, “A Review of the Use of Exemestane in Early Breast Cancer,” Therapy Clinical Risk Management, Vol. 5, No. 1, 2009, pp. 91-98.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.